Multispecific Antibody Design via Domain Segmentation

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current bispecific antibodies face challenges in production, yield, and homogeneity, limiting their effectiveness and specificity in targeting multiple biological targets.

Innovation Solution

Development of a multispecific protein format that allows for the use of a wide range of antibody variable regions, adapted for standard recombinant production techniques, with a dimeric Fc domain for enhanced binding to activating receptors like CD16A.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Adaptability or versatility

If traditional bispecific antibody formats (BiTe, DART) are used, then two different epitopes can be targeted simultaneously, but production is difficult, cell development is lengthy, and production yields are low

Engineering Contradiction:
Improveability to bind two different epitopesVSAvoidproduction yield
Core Design Contradiction:
Adaptability or versatilityVSProductivity

Solution Approach 1:

The antibody is divided into separate Fab domains (variable regions) and Fc domains (constant regions). The Fab domains are engineered to bind specific epitopes while the Fc domains mediate effector cell engagement. This segmentation allows independent optimization of binding specificity and production characteristics, resolving the contradiction between versatility and productivity.

Inventive Principle:
Principle #1Segmentation

Solution Approach 2:

The Fc domains are designed to universally bind to activating receptors (such as CD16A) on effector cells, while the Fab domains provide specific antigen binding. This multi-functionality allows the same Fc domain structure to be used across different bispecific antibody variants, standardizing production and improving yields while maintaining the ability to target different epitopes.

Inventive Principle:
Principle #6Universality (Multi-functionality)

2Reliability

If BiTe antibody format is used to activate T-cells, then T-cell activation can be achieved in proximity to tumor cells, but the antibodies are difficult to produce and cannot be produced as a homogenous protein composition

Engineering Contradiction:
ImproveT-cell activation capabilityVSAvoidprotein composition homogeneity
Core Design Contradiction:
ReliabilityVSManufacturing precision

Solution Approach 1:

Different domains of the antibody are assigned different functional qualities: the Fab domains are optimized for high-affinity antigen binding with specific structural characteristics, while the Fc domains are optimized for effector cell engagement and production homogeneity. This local differentiation of functional qualities allows T-cell activation capability to be maintained while improving manufacturing precision and protein composition uniformity.

Inventive Principle:
Principle #3Local quality

3Ease of manufacture

If conventional antibody formats are used, then standard production techniques can be applied, but the ability to bind multiple biological targets and provide immune-enhancing activity is limited

Engineering Contradiction:
Improvecompatibility with standard recombinant production techniquesVSAvoidability to bind multiple antigens and activating receptors
Core Design Contradiction:
Ease of manufactureVSAdaptability or versatility

Solution Approach 1:

The antibody structure employs asymmetric domain arrangement where Fab domains from different parent antibodies are combined with Fc domains in a non-symmetric configuration. This asymmetry enables simultaneous binding to different antigens (via diverse Fab domains) and activating receptors (via Fc domains), providing multi-target capability while maintaining compatibility with standard recombinant production techniques through modular domain assembly.

Inventive Principle:
Principle #4Asymmetry

Data Source

PatentEP3313876B1Multispecific antigen binding proteins
Publication Date: 2025.01.22 INNATE PHARMA SA
  • EP3313876B1 patent drawingFigure 1
  • EP3313876B1 patent drawingFigure 2A
  • EP3313876B1 patent drawingFigure 2B

AI summary

Multimeric multispecific proteins formed from dimerization between CH1 and CK domains and that bind two target antigens are provided. The proteins have advantages in production and in the treatment of disease, notably cancer or infectious disease.